GT health — Wise Endocrine & Metabolic Care

Patient MessagingPatients

Dr. Tashko’s 3D infographic illustrating why a lower HbA1c is not always safer after age 65. A balance scale contrasts aggressive control below 6.5% with individualized targets of 7.0%–8.0% for frail or medically complex older adults, emphasizing how excessive blood sugar lowering and hypoglycemia can increase the risks of falls, fainting, cognitive decline, and cardiovascular events.

HbA1c estimates average glucose over roughly three months, but it does not tell the whole story. In older adults, a low result may reflect excellent control. It may also reflect recurrent low glucose, excessive medication, or altered red blood cell turnover.

Therefore, the goal is not the lowest possible number. It is safe glucose control that protects health, independence, and quality of life.

HbA1c Is a Guide, Not a Grade

Many people view HbA1c like a school grade: lower must mean better. Yet averages can hide important extremes. A person moving between 45 and 250 mg/dL may match someone staying near 140 mg/dL. Their risks differ greatly.

HbA1c depends partly on how long red blood cells circulate. Anemia, blood loss, transfusion, advanced kidney disease, or related treatments can alter that lifespan. When cells disappear sooner, glucose has less time to attach, and HbA1c may appear falsely low. Therefore, direct glucose readings may reveal more than HbA1c alone.

Continuous glucose monitoring adds Time in Range, or the percentage of time glucose remains between 70 and 180 mg/dL. For many older adults, increasing stable time within this zone and minimizing time below 70 matter more than chasing a lower average. Time in Range does not replace HbA1c. Instead, it shows whether that average was achieved safely.

Why Age Changes the Treatment Equation

Age alone should never determine a diabetes target. A healthy, independent 72-year-old may reasonably pursue tighter control than a frail 72-year-old with kidney disease, memory loss, and recurrent falls. Their birth years match, but their physiology, daily demands, and treatment risks do not.

The benefits of preventing long-term complications often build over years. Hypoglycemia, however, can cause confusion, falls, fractures, seizures, or emergency care today. Older adults may lose warning symptoms and experience only fatigue, dizziness, unusual behavior, or a fall. Therefore, increasing vulnerability gives immediate safety greater influence over the target.

Reasonable HbA1c Goals Form a Continuum

The American Diabetes Association suggests the following framework for older adults. These ranges guide clinical judgment rather than replace it.

Overall health patternCommon HbA1c approachMain priority
Healthy and independent, with few stable illnessesOften below 7.0–7.5%Prevent complications while avoiding hypoglycemia
Multiple illnesses, mild cognitive change, frailty, or functional limitationsOften below 8.0%Balance benefit, safety, and treatment burden
Very complex health, advanced illness, substantial cognitive impairment, or limited functionOften avoid relying on HbA1c alonePrevent hypoglycemia and symptomatic high glucose

A less aggressive target does not mean abandoning care. Persistent high glucose can still cause dehydration, fatigue, infections, poor healing, and emergencies. Individualized care protects the patient from both ends of the spectrum.

Which Medications Deserve the Closest Review?

Insulin and sulfonylureas require special attention because they can lower glucose when the body needs less medication. Sulfonylureas include glipizide, glimepiride, and glyburide. Long-acting agents, especially glyburide, can cause prolonged hypoglycemia.

Insulin remains essential in type 1 diabetes and for some people with type 2 diabetes. Therefore, the solution is not automatic discontinuation. The better approach examines dose timing, meals, kidney function, glucose patterns, and self-management ability.

Medication review should include the entire drug list. Polypharmacy can create interactions, alter medication clearance, and hide hypoglycemia warnings. Simplifying high-risk diabetes therapy may reduce both hypoglycemia and interaction burden.

Reduction or simplification should be considered when:

  • Glucose repeatedly falls below 70 mg/dL, especially below 54 mg/dL.
  • Overnight or fasting lows suggest excessive basal insulin.
  • Daytime lows follow mealtime insulin or sulfonylurea use.
  • HbA1c falls well below the individualized goal on a high-risk medication.
  • Kidney function declines, slowing insulin or medication clearance.
  • Weight loss, poor appetite, skipped meals, or illness reduces glucose needs.
  • Memory, vision, dexterity, or caregiver support makes the plan unsafe.
  • Multiple injections, calculations, or fingersticks create excessive burden.

Severe or recurrent hypoglycemia justifies reassessment even when HbA1c appears “perfect.” Treatment may include lowering insulin, simplifying injections, or replacing a sulfonylurea. These changes need planning and glucose monitoring, not abrupt guesswork.

Lowering Risk Without Losing Meaningful Protection

Modern diabetes care looks beyond HbA1c. Some GLP-1 receptor agonists and SGLT2 inhibitors may protect the heart or kidneys beyond glucose lowering. Consequently, a low HbA1c does not automatically mean every medication should stop. Its full purpose, risks, cost, and tolerability still matter.

Continuous glucose monitoring can also warn patients or caregivers about developing lows. Still, technology should simplify life rather than exceed the patient’s ability or support system.

How These Decisions Look in Real Life

  • Case 1 — Healthy and Stable: A 70-year-old man remains active, independent, and free of hypoglycemia. His HbA1c is 7.1% on medications with low hypoglycemia risk. His current target and treatment remain reasonable.
  • Case 2 — The Misleading 6.2%: An 81-year-old woman takes basal insulin and glimepiride. She wakes sweaty and has two recent falls. Her low HbA1c looks impressive, but overnight monitoring reveals frequent hypoglycemia. Reducing high-risk therapy improves safety without causing symptomatic high glucose.
  • Case 3 — Kidney Function Changes the Dose: A 76-year-old man uses the same insulin dose for years. His kidney function declines, and fasting readings begin falling into the 60s. Lower insulin clearance changes the equation, so his dose needs reassessment.
  • Case 4 — A Regimen Becomes Too Complex: An 84-year-old woman develops memory difficulties while using multiple daily injections. Her daughter notices missed meals and duplicate doses. A simpler plan with caregiver support reduces errors and preserves independence.
  • Case 5 — Avoiding the Opposite Extreme: An 88-year-old man with frailty has thirst, frequent urination, and glucose readings above 300 mg/dL after therapy was reduced too far. His plan needs careful strengthening because comfort also requires preventing symptomatic hyperglycemia.

Why Holistic, Individualized Care Matters

The HbA1c target should connect with the whole person. We must consider cardiovascular and kidney health, cognition, mobility, nutrition, living situation, medication burden, hypoglycemia awareness, and personal priorities. These factors interact, and a change in one area can quickly alter the safest plan.

A strong strategy also evolves. The goal that worked at age 68 may no longer fit at 82 after weight loss, kidney decline, or a change in caregiver support. Conversely, an active older adult should not receive loose control merely because of age. Good diabetes care adapts without drifting toward either overtreatment or neglect.

The Takeaway

A lower HbA1c can be beneficial when it reflects stable glucose and low treatment burden. It becomes less desirable when insulin or sulfonylureas achieve that number through recurrent lows, fear, falls, or excessive complexity. In older adults, the best HbA1c is not the lowest one. It is the one that supports health, safety, function, and a life lived with confidence.

At our practice in Montgomery County, Maryland, and through virtual care, we individualize diabetes goals around each patient’s complete health picture. As an endocrinologist and diabetes specialist, Dr. Tashko connects glucose patterns, medications, kidney function, nutrition, cognition, cardiovascular risk, and daily life to create a safer and more meaningful treatment plan.

Dr. Tashko

  1. American Diabetes Association Professional Practice Committee. Older Adults: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1)–S296.
  2. American Diabetes Association Professional Practice Committee. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1)–S149.
  3. LeRoith D, et al. Treatment of Diabetes in Older Adults: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1520–1574.
  4. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. Journal of the American Geriatrics Society. 2023;71(7):2052–2081.

About Dr. Gerti Tashko, MD

Dr. Gerti Tashko, MD, is an endocrinologist in Montgomery County, Maryland. He is uniquely quadruple board-certified in endocrinology, lipidology, hypertension, and obesity medicine. His practice delivers root-cause-focused metabolic and endocrine care, available virtually and in person. He uses advanced diagnostics, personalized nutrition, and preventive medicine to improve long-term health.